2021 Q1 Form 10-Q Financial Statement
#000156459021026306 Filed on May 11, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $59.67M | $19.84M |
| YoY Change | 200.78% | |
| Cost Of Revenue | $10.41M | $3.470M |
| YoY Change | 199.97% | |
| Gross Profit | $49.27M | $16.37M |
| YoY Change | 201.02% | |
| Gross Profit Margin | 82.56% | 82.49% |
| Selling, General & Admin | $30.05M | $22.54M |
| YoY Change | 33.31% | |
| % of Gross Profit | 61.0% | 137.75% |
| Research & Development | $4.679M | $3.431M |
| YoY Change | 36.37% | |
| % of Gross Profit | 9.5% | 20.96% |
| Depreciation & Amortization | $100.0K | $97.00K |
| YoY Change | 3.09% | |
| % of Gross Profit | 0.2% | 0.59% |
| Operating Expenses | $34.73M | $25.98M |
| YoY Change | 33.71% | |
| Operating Profit | $14.53M | -$9.609M |
| YoY Change | -251.24% | |
| Interest Expense | -$7.127M | -$6.372M |
| YoY Change | 11.85% | |
| % of Operating Profit | -49.04% | |
| Other Income/Expense, Net | -$20.00K | $0.00 |
| YoY Change | ||
| Pretax Income | $7.386M | -$38.62M |
| YoY Change | -119.12% | |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | 0.0% | |
| Net Earnings | $7.386M | -$38.62M |
| YoY Change | -119.12% | |
| Net Earnings / Revenue | 12.38% | -194.66% |
| Basic Earnings Per Share | $0.13 | -$6.30 |
| Diluted Earnings Per Share | $0.13 | -$6.30 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 56.89M | 7.791M |
| Diluted Shares Outstanding | 58.81M | 7.791M |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $141.2M | |
| YoY Change | ||
| Cash & Equivalents | $141.9M | $72.27M |
| Short-Term Investments | ||
| Other Short-Term Assets | $8.600M | |
| YoY Change | ||
| Inventory | $4.400M | |
| Prepaid Expenses | ||
| Receivables | $23.60M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $177.7M | |
| YoY Change | ||
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $800.0K | |
| YoY Change | ||
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $900.0K | |
| YoY Change | ||
| Total Long-Term Assets | $159.6M | |
| YoY Change | ||
| TOTAL ASSETS | ||
| Total Short-Term Assets | $177.7M | |
| Total Long-Term Assets | $159.6M | |
| Total Assets | $337.3M | |
| YoY Change | ||
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $4.400M | |
| YoY Change | ||
| Accrued Expenses | $28.80M | |
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $33.40M | |
| YoY Change | ||
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $194.9M | |
| YoY Change | ||
| Other Long-Term Liabilities | $831.0K | |
| YoY Change | ||
| Total Long-Term Liabilities | $195.9M | |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $33.40M | |
| Total Long-Term Liabilities | $195.9M | |
| Total Liabilities | $229.4M | |
| YoY Change | ||
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | $1.000K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $107.9M | -$472.3M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $337.3M | |
| YoY Change |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $7.386M | -$38.62M |
| YoY Change | -119.12% | |
| Depreciation, Depletion And Amortization | $100.0K | $97.00K |
| YoY Change | 3.09% | |
| Cash From Operating Activities | $12.53M | -$26.70M |
| YoY Change | -146.93% | |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $4.000K | $0.00 |
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$100.0M | $0.00 |
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 12.00K | 73.76M |
| YoY Change | -99.98% | |
| NET CHANGE | ||
| Cash From Operating Activities | 12.53M | -26.70M |
| Cash From Investing Activities | -100.0M | 0.000 |
| Cash From Financing Activities | 12.00K | 73.76M |
| Net Change In Cash | -87.46M | 47.06M |
| YoY Change | -285.85% | |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $12.53M | -$26.70M |
| Capital Expenditures | $4.000K | $0.00 |
| Free Cash Flow | $12.53M | -$26.70M |
| YoY Change | -146.91% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
0 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-488195000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
97180000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
427074000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2021Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
192000 | |
| CY2020Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
212000 | |
| CY2021Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
194913000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
194250000 | |
| CY2021Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
831000 | |
| CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
893000 | |
| CY2021Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
195936000 | |
| CY2020Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
195355000 | |
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
229373000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
329894000 | |
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
585374000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
56892406 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
56890569 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
56892406 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
56890569 | |
| CY2021Q1 | us-gaap |
Gross Profit
GrossProfit
|
49265000 | |
| CY2020Q1 | us-gaap |
Gross Profit
GrossProfit
|
16366000 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4679000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3431000 | |
| CY2021Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
15506000 | |
| CY2020Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
13254000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14547000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9290000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
34732000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
25975000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
14533000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9609000 | |
| CY2020Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-22639000 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-20000 | |
| CY2021Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-7127000 | |
| CY2020Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-6372000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
7386000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-38620000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7386000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-38620000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
10445000 | |
| CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
7386000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-49065000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.13 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-6.30 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.13 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-6.30 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
56891451 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7790667 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58805285 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7790667 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
12000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3301000 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
318510205 | |
| CY2019Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
411275000 | |
| CY2020Q1 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
318510205 | |
| CY2020Q1 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
422642000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-422862000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
151000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
368000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-472330000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
7386000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-38620000 | |
| CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
100000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
97000 | |
| CY2021Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4579000 | |
| CY2020Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1786000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3301000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
368000 | |
| CY2021Q1 | hrmy |
Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
|
-50000 | |
| CY2020Q1 | hrmy |
Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
|
107000 | |
| CY2020Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1146000 | |
| CY2021Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
664000 | |
| CY2020Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
340000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1439000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
7053000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
582000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
783000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
296000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4111000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-732000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
1835000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-1509000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-2936000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-1929000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-32000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
88000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
12530000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26702000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
100000000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-100004000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
200000000 | |
| CY2020Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
5804000 | |
| CY2020Q1 | us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
102538000 | |
| CY2020Q1 | hrmy |
Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
|
-18047000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
12000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
151000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
73762000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-87462000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
47060000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
229381000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25207000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
141919000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
72267000 | |
| CY2021Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
6510000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
6214000 | |
| CY2021Q1 | hrmy |
Cash Paid For Milestones
CashPaidForMilestones
|
100000000 | |
| CY2020Q1 | hrmy |
Warrant Financing
WarrantFinancing
|
2359000 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.77%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the <font style="Background-color:#FFFFFF;">Condensed</font> Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of March 31, 2021, three customers accounted for 100% of gross accounts receivable, Caremark LLC (“CVS Caremark”), which accounted for 34% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 36% of gross accounts receivable; and Accredo Health Group, Inc. (“Accredo”), which accounted for 30% of gross accounts receivable. As of December 31, 2020, three customers accounted for 100% of gross accounts receivable, CVS Caremark, which accounted for 44% of gross accounts receivable; Pantherx, which accounted for 23% of gross accounts receivable; and Accredo, which accounted for 33% of gross accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 35% of gross product revenues; Pantherx accounted for 38% of gross product revenues; and Accredo accounted for 27% of gross product revenues. For the three months ended March 31, 2020 three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 42% of gross product revenues; Pantherx accounted for 35% of gross product revenues; and Accredo accounted for 23% of gross product revenues.</p> <p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable. </p> <p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on a single source supplier for its product and active pharmaceutical ingredient. </p> | |
| CY2020Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
410239 | |
| CY2020Q3 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-8.215 | |
| CY2020Q3 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.1217 | |
| CY2020Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
135435000 | |
| CY2021Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
1653000 | |
| CY2020Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
2454000 | |
| CY2021Q1 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
773000 | |
| CY2020Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
396000 | |
| CY2021Q1 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1585000 | |
| CY2020Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
2660000 | |
| CY2021Q1 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2356000 | |
| CY2020Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
941000 | |
| CY2021Q1 | us-gaap |
Inventory Gross
InventoryGross
|
4714000 | |
| CY2020Q4 | us-gaap |
Inventory Gross
InventoryGross
|
3997000 | |
| CY2021Q1 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
309000 | |
| CY2020Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
174000 | |
| CY2019Q4 | hrmy |
License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
|
75000000 | |
| CY2020 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P10Y | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P9Y | |
| CY2020 | us-gaap |
Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
|
P8Y6M | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
13927000 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
|
18569000 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
|
18569000 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
|
18569000 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
|
18569000 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
88203000 | |
| CY2021Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
175000000 | |
| CY2020Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
175000000 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
17236000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
12657000 | |
| CY2019Q3 | hrmy |
License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
|
2000000 | |
| CY2021Q1 | hrmy |
License Agreement Milestone Payments Due
LicenseAgreementMilestonePaymentsDue
|
100000000 | |
| CY2019Q3 | hrmy |
License Agreement Additional Milestone Payments Due
LicenseAgreementAdditionalMilestonePaymentsDue
|
102000000 | |
| CY2019Q3 | hrmy |
Licensing Agreement Milestone Fees
LicensingAgreementMilestoneFees
|
2000000 | |
| CY2021Q1 | hrmy |
Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
|
9492000 | |
| CY2020Q4 | hrmy |
Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
|
7803000 | |
| CY2021Q1 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1891000 | |
| CY2020Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1905000 | |
| CY2021Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
9512000 | |
| CY2020Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
9006000 | |
| CY2019 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
0 | |
| CY2020Q3 | us-gaap |
Preferred Stock Conversion Basis
PreferredStockConversionBasis
|
1-for-8.215 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6265911 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
17.66 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
35.44 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
8.22 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.22 | |
| CY2020Q3 | hrmy |
Preferred Stock Conversion Ratio
PreferredStockConversionRatio
|
0.1217 | |
| CY2021Q1 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
one vote for each share | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5210832 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1112606 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
1837 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
55690 | |
| CY2021Q1 | hrmy |
Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
|
1478000 | |
| CY2020Q4 | hrmy |
Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
|
1081000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1006000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
746000 | |
| CY2021Q1 | hrmy |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
882000 | |
| CY2020Q4 | hrmy |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
2186000 | |
| CY2020Q4 | hrmy |
Accrued Milestone Payment Current
AccruedMilestonePaymentCurrent
|
100000000 | |
| CY2021Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
136000 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
204000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
401000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
875000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
892000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
334000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
2502000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
20.90 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y7M17D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y7M24D | |
| CY2021Q1 | hrmy |
Share Based Compensation Expense Income
ShareBasedCompensationExpenseIncome
|
-10000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.6000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.5500 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.9580 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0066 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0032 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0119 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0056 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
11.99 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.06 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3251000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
475000 | |
| CY2020Q4 | hrmy |
Future Share Based Compensation Expenses Remainder Of Fiscal Year
FutureShareBasedCompensationExpensesRemainderOfFiscalYear
|
12920000 | |
| CY2020Q4 | hrmy |
Future Share Based Compensation Expense Year One
FutureShareBasedCompensationExpenseYearOne
|
16867000 | |
| CY2020Q4 | hrmy |
Future Share Based Compensation Expense Year Two
FutureShareBasedCompensationExpenseYearTwo
|
15880000 | |
| CY2020Q4 | hrmy |
Future Share Based Compensation Expense Year Three
FutureShareBasedCompensationExpenseYearThree
|
14900000 | |
| CY2020Q4 | hrmy |
Future Share Based Compensation Expense Year Four
FutureShareBasedCompensationExpenseYearFour
|
5831000 | |
| CY2021Q1 | hrmy |
Securities Outstanding Included In Computation Of Treasury Stock
SecuritiesOutstandingIncludedInComputationOfTreasuryStock
|
1913835 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4871609 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
41965197 | |
| CY2021Q1 | us-gaap |
Warrants And Rights Outstanding Change In Valuation Technique
WarrantsAndRightsOutstandingChangeInValuationTechnique
|
false |
